Redefining Fluoroquinolone Antibiotics: Design and Synthesis of Degradable Fluoroquinolones to Reduce Environmental Persistence Authors: Nathan Raeymackers, Emile De Mol, Martin Yenokyan, Morten Suk, Klaus Kümmerer, Thomas S A Heugebaert, Christian V Stevens Published: 2026 ABSTRACT AbstractA significant challenge associated with antibiotics, and active pharmaceutical ingredients in general, is their intentional design for high stability, which promotes environmental persistence and contributes to the development of antibiotic resistance. Ciprofloxacin, a widely used fluoroquinolone antibiotic, exemplifies this issue. Using the benign by design (BbD) approach, ciprofloxacin was redesigned into an environmentally improved fluoroquinolone molecule, termed Cip‐hemi. In this design, ciprofloxacin was modified by replacing the persistent cyclopropyl group at the N1 position with a tetrahydrofuran moiety, thereby creating a degradable linker. Herein, we report the development of an efficient and robust synthetic platform to access the Cip‐hemi scaffold, along with the preparation of a series of novel derivatives. These molecules are developed with a dual‐purpose design: to restore high‐level antibacterial action while ensuring rapid degradation in the aquatic environment. The optimized synthetic strategy minimizes the use of hazardous solvents and largely avoids labor‐intensive purification by flash chromatography, providing a streamlined approach for the preparation of environmentally improved fluoroquinolones.Keywords: benign by design, Cip‐hemi, fluoroquinolones, green chemistry, sustainable pharmacy Introduction For decades, antibiotics have served as the primary defense against bacterial infections. Nonetheless, their widespread and often indiscriminate use has inadvertently accelerated the emergence and spread of antibiotic‐resistant bacteria. Mestrovic et al. estimated that approximately 541,000 deaths were associated with antimicrobial resistance (AMR) in the European region in 2019. AMR therefore represents one of the most serious threats to global public health [1]. A substantial fraction (40%–90%) of administered antibiotics is excreted in the unchanged form. Animal husbandry, industrial effluents, and municipal wastewater represent major pathways through which antibiotics enter aquatic and terrestrial ecosystems [2]. Moreover, conventional wastewater treatment plants do not achieve complete removal of antibiotic residues, and only about half of the globally generated human wastewater is treated. Consequently, biologically active antibiotic residues can persist, enter, and accumulate in the environment [3, 4]. While fluoroquinolones rank among the most prescribed antibiotics, these molecules are also known for their biological persistence. Van Doorslaer et al. reported a worldwide median concentration of fluoroquinolones in freshwater surface water of 26 ng/L [5]. For ciprofloxacin, one of the most commonly used fluoroquinolones, an average concentration of 19 µg/L has been reported in surface waters [6]. In contrast, concentrations of up to 14 mg/L have been detected in surface waters near bulk pharmaceutical production facilities in India [7]. Such sublethal concentrations, which lie below the minimum inhibitory concentration, exert selective pressure on bacterial populations, thereby promoting the survival and growth of resistant strains [8, 9, 10, 11, 12]. The benign by design (BbD) concept offers a promising approach to address this challenge. BbD promotes consideration of a chemical's end‐of‐life properties, such as environmental fate and ecotoxicity, at the earliest stages of molecular design. Traditionally, active pharmaceutical ingredients (APIs) are developed to maximize chemical and metabolic stability. As a result, BbD principles are rarely integrated into pharmaceutical research and development. However, a survey conducted by Puhlmann et al. among industrial R&D and environmental experts highlighted that there is a window of opportunity to design APIs that retain therapeutic efficacy while exhibiting improved environmental profiles [13, 14, 15]. To our knowledge, no marketed active pharmaceutical ingredient has been deliberately developed with end‐of‐life considerations in mind. Nevertheless, approximately 15%–20% of marketed drugs are estimated to be environmentally biodegradable, underscoring that environmental biodegradability can be incorporated without compromising the pharmacological activity [16]. Several academic case studies have demonstrated that molecular redesign can lead to improved environmental properties. For example, in the β‐blockers metoprolol and propranolol, selective introduction of additional hydroxyl groups preserved the desired pharmacological activity while significantly enhancing biodegradability [17, 18, 19]. Leder and coworkers developed an environmentally improved fluoroquinolone, Cip‐hemi. In this compound, the persistent cyclopropyl group at the N1 position of ciprofloxacin was replaced by a hemiaminal ether, thereby introducing a degradable linker (Figure 1). Upon hydrolysis, this linker is cleaved to form the transformation product Cip‐d‐CP. The antibacterial activity of Cip‐hemi lies between that of first‐ and second‐generation fluoroquinolones. Following hydrolysis of the degradable linker, the antibacterial activity is reduced by at least one order of magnitude, thereby potentially lowering the selective pressure for the development of antibiotic‐resistant bacteria in the environment [20]. Ciprofloxacin and Cip‐hemi molecules are shown. On the bottom, the partial hydrolysis followed by biodegradation of the linker of Cip‐hemi is visualized. Adapted from ACS Sustainable Chem., 2021 [20]. Additionally, Suk and coworkers showed that the 4‐quinolone‐3‐carboxylic acid heterocycle is readily biodegradable under OECD guidelines (Figure 2) [21]. Therefore, this scaffold could potentially serve as a biodegradable backbone for new quinolone antibiotics. M. Suk and coworkers proved that heterocycle 4‐quinolone‐3‐carboxylic acid is readily biodegradable following OECD guidelines [21]. In this work, we first report the development of an efficient, streamlined synthesis for the Cip‐hemi scaffold. Building on this foundation, we introduce novel derivatives designed to overcome the current tenfold potency gap compared to ciprofloxacin. These structures are developed with a dual‐purpose design: to restore high‐level antibacterial action while ensuring rapid degradation in the aquatic environment. These compounds will later be evaluated for both their biodegradability and antibacterial activity. No prior literature is addressing this topic; a German patent provides the only existing synthetic precedent for this scaffold [22]. The original ciprofloxacin synthesis was developed by Klaus Grohe at Bayer AG, affording a patented process consisting of seven steps with an overall isolated yield of 49%. This synthetic route has since served as the foundation for the preparation of numerous fluoroquinolone antibiotics. Nevertheless, considerable efforts have been directed toward its optimization. Notably, Lin and coworkers reported a telescoped continuous‐flow approach, which reduced the residence time from 24 h to 9 min and improved the yield to 60% [23, 24, 25, 26]. The synthesis of Cip‐hemi via this pathway is hindered by the requirement for 2‐aminotetrahydrofuran (Figure 3), a noncommercial intermediate for which no literature synthesis or isolation protocols exist. Furthermore, its application is rendered unfeasible by its inherent instability under the rigorous ring‐closing conditions, largely due to its tendency to undergo spontaneous ring opening or uncontrolled polymerization. A more viable synthetic strategy involves carrying out the ring‐closing step prior to the incorporation of the tetrahydrofuran moiety, as also outlined in the corresponding patent. However, its total synthesis remains inefficient. Overview of the theoretical synthesis routes of Cip‐hemi. Results and Discussion Cip‐Hemi Synthesis The newly developed synthesis platform is depicted in Figure 4. It starts with the well‐established Gould–Jacobs reaction to construct the 4‐quinolone core. Subsequently, the tetrahydrofuran ring is coupled to the nitrogen atom. Finally, an aromatic nucleophilic substitution followed by saponification affords the sodium salt of the fluoroquinolone‐hemi molecule. Newly developed synthesis platform for Cip‐hemi and derivatives. This research prioritized the development of a robust and streamlined synthetic framework. Complete optimization toward a fully sustainable total synthesis was not feasible within the timeframe of this work. Nevertheless, the route was deliberately designed to eliminate chromatographic purification, thereby substantially improving the process efficiency. Additionally, by replacing high‐risk “red‐flag” solvents—such as DMF and dioxane—with greener alternatives, we intended to align process efficiency with environmental responsibility. Prior to initiating the synthesis of derivatives, the platform was optimized for the preparation of Cip‐hemi [27]. First, the condensation between 3,4‐difluoro aniline and diethyl ethoxymethylene malonate was carried out under solvent‐free conditions at 105 °C for 3 h, affording full conversion and a quantitative yield. The subsequent Gould–Jacobs reaction is traditionally performed in refluxing diphenyl ether, affording an isolated yield of 78% (Figure 5) [28, 29]. Condensation and subsequent Gould–Jacobs reaction are shown. The yields are given for both difluoro (a) and monofluoro (b) intermediates. Diphenyl ether is not considered a preferred solvent in chemical synthesis from a green chemistry perspective. Therefore, efforts have been made to improve the sustainability and the overall performance of this reaction. Several research groups have demonstrated that the transformation can be conducted in a (high‐pressure) continuous‐flow reactor, thereby eliminating the need for diphenyl ether while enhancing both efficiency and reproducibility [30, 31]. However, as access to such a high‐pressure continuous‐flow system was not available during this work, the traditional batch procedure in diphenyl ether was employed in this work. Next, the C—N coupling emerged as the bottleneck of the synthetic sequence (Figure 6). The original conditions were based on the work by Yamashita and coworkers for a similar C—N coupling in the synthesis of tegafur, involving a substitution reaction in DMF at 120 °C. Comparable conditions were later demonstrated by Zasada et al. [32, 33]. C—N coupling proceeds optimally under Vorbrüggen conditions. The yields are given for both difluoro (a) and monofluoro (b) intermediates. Accordingly, different additives (predominantly bases), acetal leaving groups, and time–temperature conditions were screened, as summarized in Table 1 (entries 1–12) [34, 35]. A closed reaction system was employed to prevent shifting the equilibrium from the activated acetal towards dihydrofuran. Conversions were determined by 1H‐NMR analysis. The addition of bases did not improve conversion; in fact, the highest conversions were achieved in the absence of additives. Furthermore, acetate proved to be a more favorable leaving group than benzoate. Considering both conversion and atom economy, the reaction system was subsequently intensified by eliminating additives and employing acetate as the leaving group. TABLE 1Overview of the screening conditions for the N‐alkylation is shown.a EntryLeaving groupBase, 2 equiv.SolventTime, hTemperature, °CConversion, % 1 Acetate (2 equiv.)—DMF212065 2 Acetate (2 equiv.)—DMF249047 3 Acetate (2 equiv.)DBUDMF21208 4 Acetate (2 equiv.)DBUDMF249010 5 Acetate (2 equiv.)NaOAcDMF21200 6 Acetate (2 equiv.)NaOAcDMF24900 7 Acetate (2 equiv.)DMAP, 0.05 equiv.DMF29010 8 Acetate (2 equiv.)—DMSO2120CRMb 9 Acetate (2 equiv.)—DMSO29030 10 Benzoate (2 equiv.)—DMF212047 11 Benzoate (2 equiv.)DBUDMF249025 12 Benzoate (2 equiv.)NaOAcDMF24908 13 Acetate (2 equiv.)—DMF212065 14 Acetate (2 equiv.)—DMF612042 15 Acetate (2 equiv.)—DMF113070 16 Acetate (2 equiv.)—DMF213068 17 Acetate (3 equiv.)—DMF212069 18 Acetate (3 equiv.)—DMF212070 19 Acetate (5 equiv.)—DMF212076 20 Acetate (5 equiv.)—DMF212077 Note: Conversion was determined by 1H‐NMR spectroscopy.a Reactions were performed in dry DMF on a 100 mg scale, unless stated otherwise.b Complex reaction mixture. Overview of the screening conditions for the N‐alkylation is shown.a Note: Conversion was determined by 1H‐NMR spectroscopy. Reactions were performed in dry DMF on a 100 mg scale, unless stated otherwise. Complex reaction mixture. Initial attempts focused on elevating the reaction temperature and extending the reaction time (Table 1, entries 13–20). However, these adjustments did not lead to full conversion, and prolonged reaction times even promoted product degradation. Similarly, increasing the equivalents of the activated acetal failed to push the reaction to full conversion, affording only a modest improvement. The most optimized reaction conditions (Table 1, entries 19–20) were evaluated on a 1.5 mmol scale in a flame‐dried, closed pressure tube. The reaction mixture was stirred for 2 h at 120 °C with five equivalents of 2‐acetoxy‐THF. After an alkaline work‐up and selective precipitation of the starting material, the product was obtained in an isolated yield of 35%. The reliance on toxic DMF, combined with incomplete conversion and modest yields, necessitated the development of alternative synthetic methodologies. The Vorbrüggen reaction, commonly employed in nucleoside synthesis, proved to be the most promising approach. This methodology involves in situ silylation of the nucleobase, followed by a Lewis acid‐catalyzed, glycosylation with a peracetylated sugar. We observed that silylation of the 4‐quinolone core also significantly enhances solubility as the molecule is otherwise poorly soluble due to strong π‐π stacking interactions. Among the Lewis acids commonly employed in the Vorbrüggen reaction, SnCl4 and TMSOTf are the most frequently used [36, 37, 38, 39, 40]. Therefore, the Vorbrüggen coupling was tested with these two Lewis acids (Table 2). The reaction was performed in dry acetonitrile, and conversion was determined by 1H‐NMR. Whereas TMSOTf failed to initiate the reaction, the employment of SnCl4 proved highly superior, delivering the desired product in a quantitative isolated yield (Figure 6). Although SnCl4 afforded the best results under the conditions investigated, future optimization could explore its replacement with a more sustainable Lewis acid for the Vorbrüggen C—N coupling. TABLE 2Screening conditions for the Vorbrüggen type C—N coupling.EntryScale, mmolSilylating agentLewis acid2‐Acetoxy THFConditionsConversion, % 1 1BSASnCl4 (1 equiv.)5RT, 1 hCRMa 2 1BSASnCl4 (1 equiv.)50 °C, 1 h100 3 2BSASnCl4 (1 equiv.)20 °C, 30 min100 4 0.5BSATMSOTf (1 equiv.)20 °C, 30 min0 5 0.5BSATMSOTf (1 equiv.)2RT, 30 min0 6 0.5BSATMSOTf (2 equiv.)250 °C, 3 h0 7 0.5BSATMSOTf (2 equiv.)280 °C, 3 h0 8 0.5BSATMSOTf (2 equiv.)280 °C, 16 h0 Note: Conversion was determined by 1H‐NMR spectroscopy.a Complex reaction mixture. Screening conditions for the Vorbrüggen type C—N coupling. Note: Conversion was determined by 1H‐NMR spectroscopy. Complex reaction mixture. The subsequent nucleophilic aromatic substitution (SNAr) and saponification steps follow the Grohe pathway used in the ciprofloxacin synthesis. In the original work, the piperazine moiety is Cbz‐protected, although this protection looks unnecessary for the present synthesis [22]. According to literature reports, SNAr reactions are typically carried out in polar, aprotic solvents (acetonitrile, DMSO, and dioxane) for extended periods (up to several days) at elevated temperatures in the presence of bases such as triethylamine [41, 42]. However, in our experiments, triethylamine did not enhance reactivity. Initial experiments utilized eight equivalents of piperazine in dioxane to ensure full conversion within 16 h. However, this large excess of the reagent, combined with the solvent system, resulted in significant product loss during the washing step of compound 7 (Figure 7, top). SNAr reaction and one pot SNAr combined with saponification reaction results. Following the approach of Lin and coworkers, a one‐pot procedure integrating the SNAr reaction and subsequent saponification was successfully implemented. This transition enabled increasing the yield and replacing the toxic dioxane solvent with DMSO. Due to the inherent acid sensitivity of the molecule, a final acidification was not feasible. Therefore, the final product was isolated as its corresponding sodium salt (Figure 7, bottom) [24]. The one‐pot SNAr and saponification followed by antisolvent crystallization using acetone enabled selective precipitation of the product while retaining piperazine in solution, affording an isolated yield of 96%. Over the complete synthetic sequence of five steps, an overall isolated yield of 75% was obtained. By eliminating labor‐intensive intermediate purifications, the entire sequence was streamlined into a robust process that concludes with efficient antisolvent crystallization. Structure–Activity Relationship and Synthesis of Derivatives The goal of this work is to develop environmentally improved (fluoro)quinolone derivatives that retain antibacterial activity comparable to that of second‐generation fluoroquinolones while further enhancing biodegradability. Cip‐hemi serves as a proof of concept for this approach. By employing the same degradable linker, a series of related derivatives were synthesized and will be evaluated for both bioactivity and biodegradability. The structure–activity relationship (SAR) of quinolones is well established, and schematic overviews as shown in Figure 8 are widely available in the literature. Structural modifications at positions 2, 3, and 4 are rare due to their critical role in maintaining DNA–gyrase binding affinity. In this work, attention is directed towards derivatives featuring structural variability at positions 6, 7, and 8, which have been identified as the most influential sites for modulating biological activity [43]. Structure–activity relationship of fluoroquinolones. Reproduced from Med. Chem. Comm., 2019 with permission of The Royal Society of Chemistry [43]. The N1 position was retained as in the Cip‐hemi. Docking and quantitative SAR studies indicate that only a limited space is available in the binding pocket surrounding this position [44, 45, 46]. Consequently, the introduction of larger substituents at N1 is not expected to be beneficial. In addition, the four‐membered ring system 2‐acetoxyoxetane appears to be synthetically inaccessible based on available literature reports, and its intrinsic stability may present further challenges. In second‐generation quinolones, a fluorine atom was introduced at position 6 to enhance the antibacterial activity. Consequently, most commercially available fluoroquinolone antibiotics incorporate this substitution. However, Van Bambeke et al. proposed that, when other substituents are appropriately optimized, removal of the fluorine at position 6 remains feasible without a significant loss of activity [47]. New compounds have emerged within this subclass of fourth‐generation quinolones, which are collectively referred to as des‐fluoroquinolones [48, 49, 50, 51]. Importantly, cleavage at both the N1 and C7 positions of the new des‐fluoro derivatives may result in the formation of 4‐quinolone‐3‐carboxylic acid, which is anticipated to be biodegradable. Accordingly, this work focuses on derivatives with and without fluorine substitution at the C6 position. The C7 position allows for the greatest degree of structural variability among quinolones. Substitution with various heterocyclic amines is most commonly observed [52, 53]. In addition to the emergence of naphthyridone‐based quinolones, several derivatives bearing small substituents at the C8 position have been reported. Introduction of fluorine, chlorine, methoxy, or methyl groups at this site has been shown to enhance potency or broaden the antibacterial activity spectrum [43, 53]. Naphthyridone‐based derivatives are not discussed in this work, as they require an alternative synthetic route [54, 55]. Furthermore, only a small minority of commercially available fluoroquinolones feature substitution at the R5 position. Although certain R5 modifications have been associated with enhanced in vitro activity, these effects are not consistently reflected in vivo. Therefore, structural variation at this site was not considered in the present study [43, 47, 53]. Unfortunately, substituents at position 8 were found to be incompatible with the newly developed synthesis platform (Figure 9). Both fluoro and methoxy substituents did not afford the desired C—N coupling under Vorbrüggen glycosylation conditions. Consequently, the focus of the structural variation was redirected toward modifications at positions 6 and 7. The modifications at the C7 position were mostly derived from structural motifs found in commercially available fluoroquinolones. Vorbrüggen C—N coupling not possible with substitutions at C8 position. Using the established synthesis platform, 14 new derivatives were synthesized (Figure 10). The synthesis of intermediate 6a and its monofluorinated analog 6b is largely similar, and both serve as common intermediates (Figures 5 and 6). For compounds 8–14, the SNAr reaction was performed by stirring overnight at 60 °C under an argon atmosphere, and the subsequent saponification was performed in the established one‐pot reaction. Overview of the synthesized derivatives and the corresponding overall yields. *During the synthesis of these derivatives, an intermediate reversed phase flash chromatography purification of the ethyl ester was needed. A minor complication in the one‐pot SNAr and saponification sequence involved the generation of fluoride salts as a byproduct of nucleophilic displacement (1–6 wt%). These salts were only partially removed during the antisolvent recrystallisation. Introducing an intermediate work‐up after the S N Ar drastically lowers the isolated yield. Furthermore, acidification of the reaction mixture is not feasible as it induces degradation of the product. The residual fluoride fractions were quantified through F‐NMR analysis (supporting information), and yields were adjusted accordingly. For compounds 15–20, the amine was used in its salt form during the SNAr reaction, rendering the one‐pot approach unsuitable. Consequently, the SNAr and saponification reactions were decoupled by isolating the ethyl ester intermediate. The use of amine salts necessitated an additional neutralization step and more extensive work‐up procedures (Tables 3 and 4). Next, a suitable solvent system for the saponification reaction was sought. The use of DMSO was precluded by its high boiling point and persistence, while acetonitrile proved unsuitable due to the formation of sodium acetate when exposed to the saponification conditions (Supporting Information). Therefore, methanol was selected as the solvent for the saponification reactions to overcome the limitations associated with DMSO and acetonitrile. TABLE 3Overview of the SNAr reaction and isolation of the fluoro ethyl ester intermediates.a CpdAmineEquiv.SolventBaseTime, hTemperature, °CExtraction solventIsolated yield Et‐15 3DMSOK3PO4 (3 equiv.)540EtOAc16%DCM23% Et‐17 5DMSOK2CO3 (10 equiv.)560EtOAc59%TEA (12 equiv.)71% Et‐19 5MeCNK2CO3 (10 equiv.)260EtOAc60% Et‐21 5MeCNK3PO4 (1 equiv.)240EtOAc65%a During the SNAr reaction using amine salts, a neutralization and extra work‐up were performed to isolate the ethyl ester intermediate (Et‐xx). The saponification reaction is performed in methanol. Overview of the SNAr reaction and isolation of the fluoro ethyl ester intermediates.a During the SNAr reaction using amine salts, a neutralization and extra work‐up were performed to isolate the ethyl ester intermediate (Et‐xx). The saponification reaction is performed in methanol. TABLE 4Overview of the SNAr reaction and isolation of the des‐fluoro ethyl ester intermediates.a CpdAmineEquiv.SolventBaseTime, hTemperature, °CExtraction solventIsolated yield Et‐16 5DMSOK3PO4 (5 equiv.)2460DCM39% Et‐18 5DMSOK3PO4 (10 equiv.)48100EtOAcOily DMSO solvateDCM60%b Et‐20 5DMSOK3PO4 (10 equiv.)48100EtOAcOily DMSO solvateDCM30%b Et‐22 5DMSOK3PO4 (1 equiv.)740EtOAc37%a During the S N Ar reaction using amine salts, a neutralization and extra work‐up were performed to isolate the ethyl ester intermediate (Et‐xx). The saponification reaction is performed in methanol.b After reversed phase flash chromatography. Overview of the SNAr reaction and isolation of the des‐fluoro ethyl ester intermediates.a During the S N Ar reaction using amine salts, a neutralization and extra work‐up were performed to isolate the ethyl ester intermediate (Et‐xx). The saponification reaction is performed in methanol. After reversed phase flash chromatography. Since SNAr reactions are generally characterized by relatively low intrinsic reactivity, large excesses of both the amine and bases are required to achieve acceptable conversion. This, in turn, leads to the formation of substantial amounts of inorganic salts, which tend to accumulate at the interphase and adsorb the product, thereby complicating isolation and reducing isolated yields. Different conditions and bases were evaluated during the coupling, and the results are summarized in Tables 3 and 4 for the, respectively, fluorinated and nonfluorinated derivatives. The work‐up of the SNAr reaction of compound Et‐15 was initially hampered by the accumulation of insoluble salt fractions at the interface, which led to significant product loss through adsorption. Consequently, a screening of bases (triethylamine, K2CO3, and K3PO4) and extraction solvents (ethyl acetate, 2‐MeTHF, butyl acetate, and dichloromethane) was conducted. Among these, K3PO4 proved to be most effective in mitigating the formation of insoluble residues. An isolated yield of 16% was achieved using three equivalents of amine and K3PO4 combined with extraction in ethyl acetate. Using dichloromethane, the yield did not increase significantly. In contrast, reactions and isolation procedures involving 3‐amino‐N,N‐dimethylpyrrolidin (Et‐17) and 3‐amino‐N‐methylpyrrolidin (Et‐19) as nucleophiles proceeded more smoothly, affording moderate isolated yields (Table 3). The C7 position of the des‐fluoro derivatives (Table 4) is significantly deactivated toward SNAr reactions due to the replacement of the C6‐fluorine with a hydrogen atom, which lacks the necessary inductive electron‐withdrawing effect. Consequently, harsher reaction conditions (extended heating at higher temperatures) are required, leading to the formation of numerous byproducts that complicate the precipitation of the final product. Compound Et‐16 was extracted with dichloromethane to minimize the formation of a viscous oil arising from the residual ethyl acetate and DMSO. Furthermore, these complications were especially pronounced for compounds Et‐18 and Et‐20, necessitating additional reversed‐phase flash chromatography purification. For these derivatives, the established synthesis and work‐up protocol proved unsuitable as product precipitation was not possible. For compounds 21 and 22, the SNAr and subsequent saponification with octahydro‐1H‐pyrrolo[3,4‐b]pyridine in its free‐amine form were expected to be compatible with the established one‐pot procedure. Direct isolation of 21 using precipitation from DMSO proved challenging. Despite multiple attempts, combined isolated yields (SNAr and saponification) consistently remained below 15%, rendering the typical workflow unsuitable for this substrate. Consequently, the corresponding ethyl ester intermediates Et‐21 and Et‐22 were first isolated through an aqueous work‐up, obtaining improved yields (Tables 3 and 4). Several products contain two or more chiral centers. During the C—N coupling, the chirality of 2‐acetoxy‐THF is lost upon the elimination of acetic acid, resulting in a nonenantioselective transformation. For compounds 21 and 22, the products were obtained as a mixture of diastereomers, as the amine was purchased in an enantiomerically pure form (4aS,7aS). This is clearly reflected in the peak splitting observed in the LC–MS chromatograms and 19F‐NMR spectrum (Supporting Information). For compounds 10, 13, 14, and 17‐20, the amines were purchased as racemic mixtures, and the corresponding products were therefore isolated as two racemic diastereomers. This is evident from the multiplicity observed in the 19F‐NMR spectra of the fluorinated derivatives, whereas the resolving power of the 1H‐NMR spectra and LC–MS chromatograms was insufficient to distinguish the individual diastereomers. Preliminary Biological Evaluation To validate the “benign‐by‐design” character of these analogs, a highly comprehensive biological evaluation is required. A complete biological profile requires systematic antimicrobial screening to determine minimum inhibitory concentrations (MICs) against target pathogens, ready and inherent biodegradation assays to track environmental persistence, pH‐dependent degradation studies to monitor rapid decomposition under acidic conditions, and ecotoxicity assessments on nontarget environmental organisms. As the required biological evaluation extends beyond a basic assessment of antimicrobial activity, it falls outside the scope of the present work. Biological assays will be conducted by specialized partner laboratories within the framework of the European TransPharm consortium. Nevertheless, selected preliminary biological data are presented to provide an initial indication of the environmental performance of the developed analogs. Selected derivatives were subjected to biodegradation testing according to OECD 301D using the Closed Bottle Test. The resulting transformation products were analyzed and identified by UPLC–HRMS. Full experimental details and results are provided in the Supporting Information. The results indicated that none of the investigated fluoroquinolone derivatives exhibited significant biodegradation in the Closed Bottle Test (Tables 5 and S1). Nevertheless, HRMS analysis revealed partial transformation through the hydrolytic cleavage of the hemiaminal ether linker (Table S2). These preliminary findings suggest that the ready biodegradability of fluoroquinolones under CBT conditions is not governed solely by fluorination at C6 but is also strongly influenced by the overall structure of the pharmacophore and its highly substituted quinolone core. TABLE 5Preliminary biodegradation testing results.CpdBiodegradability, % ThODResult 9 6 ± 0.3NRB 10 1 ± 5.5NRB 11 2 ± 0.5NRB 12 3 ± 0.7NRB 13 −1 ± 0.8NRB 14 0 ± 2.0NRBAbbreviation: NRB, not readily biodegradable. Preliminary biodegradation testing results. Abbreviation: NRB, not readily biodegradable. Although the investigated derivatives exhibited biodegradability comparable to that of approved fluoroquinolones, the cleavage of the tetrahydrofuranyl substituent at N1 is expected to reduce their antimicrobial activity. This loss of activity has previously been demonstrated for the structurally related CIP‐hemi and its transformation product CIP‐d‐CP, whereas approved fluoroquinolones such as ciprofloxacin are hydrolytically stable [20, 21]. Since cleavage of the hemiaminal ether is an acid‐catalyzed abiotic process, transformation may already begin following excretion into the urine. Importantly, hydrolysis of this linker was also observed under the slightly alkaline conditions of the biodegradation test for all the tested compounds. The results further suggest that hydrolysis is not strongly affected by fluorination at C6 or structural variation at C7. Suitable modification of the C7 substituent may therefore offer an opportunity to improve antimicrobial potency and broaden the activity spectrum while retaining the hydrolytic deactivation mechanism. In addition to hydrolysis at the N1 position, oxidation of the primary alcohol moiety in compounds 11 and 12 to the corresponding carboxylic acid was observed in the presence of the applied inoculum (Table S2). This transformation may represent an initial step toward further degradation and suggests that structural modifications at the C7 substituent could provide an additional mechanism for environmental transformation and deactivation. However, definitive conclusions cannot be drawn from the available data, and a more comprehensive biological evaluation is required. Nevertheless, these preliminary results indicate that the newly synthesized fluoroquinolones exhibit degradation and potential deactivation profiles comparable to those of CIP‐hemi, supporting their further investigation as potentially more environmentally benign fluoroquinolone derivatives. Conclusion An efficient, robust synthetic framework for Cip‐hemi and its related quinolone derivatives was successfully established. The C—N coupling step initially represented a significant synthetic bottleneck. However, this challenge was successfully addressed by implementing the Vorbrüggen methodology. Furthermore, the SNAr reaction and saponification were, in some cases, performed in a one‐pot sequence, which reduces the need to isolate intermediates and streamlines the synthetic sequence. Overall, this work demonstrated the synthetic incorporation of a degradable linker into quinolone derivatives. Achieving truly sustainable pharmaceuticals demands more than molecular redesign alone. While BbD provides a critical foundation, equally important is the development of greener and more efficient synthetic routes. Although the optimized route minimizes the use of hazardous solvents and generally avoids the need for chromatographic purifications, the overall synthetic pathway cannot yet be considered fully sustainable. Further optimization should therefore focus on improving the sustainability of the synthetic pathway. These novel derivatives were designed to reduce the environmental persistence of antibiotics by incorporating the degradable linker of the Cip‐hemi. Additional structural variation was introduced with the aim of improving the antimicrobial activity and/or biodegradability. Preliminary testing showed no significant biodegradation in the Closed Bottle Test. Nevertheless, all evaluated derivatives underwent partial transformation through hydrolytic cleavage of the hemiaminal ether linker, indicating retention of the intended N1 deactivation mechanism. Although none of the evaluated derivatives in the preliminary biotesting met the criteria for ready biodegradability in the Closed Bottle Test, all underwent hydrolytic cleavage of the hemiaminal ether linker, demonstrating that the intended N1 deactivation mechanism was retained across the newly developed compound series. Moreover, oxidation of the primary alcohol at the C7 substituent of compounds 11 and 12 revealed an additional opportunity to promote environmental transformation through the rational modification of this position. These findings establish a promising foundation for the continued molecular design of fluoroquinolones, in which antimicrobial performance and multiple deactivation pathways can be optimized independently. Although these findings support further investigation of the derivatives as potentially more environmentally benign fluoroquinolones, comprehensive biological testing is required to validate the proposed molecular designs. This evaluation will be conducted in a follow‐up study and therefore falls outside the scope of the present work. Author Contributions Nathan Raeymackers : lab experiments, analysis, writing, and conceptualization. Emile De Mol : lab experiments, analysis, and writing. Martin Yenokyan : lab experiments and analysis. Morten Suk: lab experiments biotesting. Klaus Kümmerer : methodology. Thomas S. A. Heugebaert : conceptualization and review – editing. Christian V. Stevens : conceptualization, review – editing, supervision, project administration, and funding acquisition. Funding This work was supported by the European Health and Digital Executive Agency (101057816—TransPharm). Conflicts of Interest The authors declare no conflicts of interest. Supporting information The experimental part, including synthesis protocols, product characterization, materials and methods, and spectral data are provided in the Supporting Information. The authors have cited additional references within the Supporting Information [56, 57, 58, 59]. Acknowledgments This work has received funding from the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement No. 101057816. Data Availability Statement The data that support the findings of this study are available in the Supporting Information. References Associated Data Supplementary Materials The experimental part, including synthesis protocols, product characterization, materials and methods, and spectral data are provided in the Supporting Information. The authors have cited additional references within the Supporting Information [56, 57, 58, 59]. Data Availability Statement The data that support the findings of this study are available in the Supporting Information.